Renal amyloidosis associated with extracapillary glomerulonephritis and vasculitis in a patient with inflammatory bowel disease treated with infliximab

Clinical Nephrology

Volumn 70, Issue 3, 2008, Pages 240-244

  Hatakeyama, T ^a   Komatsuda, A ^a   Matsuda, A ^a   Togashi, M ^a   Maki, N ^a   Masai, R ^a   Sawada, K ^a   Wakui, H ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amyloid A protein; Crescent formation; Inflammatory bowel disease; Infliximab; Vasculitis

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; CONGO RED; CREATININE; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; PREDNISOLONE;

AGED; ARTERY WALL; ARTICLE; CAPILLARY WALL; CASE REPORT; CLINICAL EXAMINATION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; ENTERITIS; FEMALE; FOLLOW UP; GLOMERULUS CAPILLARY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE RESECTION; INTESTINE ULCER; JAPANESE; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; MESANGIUM; PERIODIC ACID SCHIFF STAIN; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; TREATMENT OUTCOME; VASCULITIS;

EID: 52149108718     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70240     Document Type: Article

References (13)

1. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor α agents. Semin Arthritis Rheum. 2008; 37: 381-387.
2. Drewe E, Huggins ML, Morgan AG, Cassidy MJD, Powell RJ. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology. 2004; 43: 1405-1408.
3. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 2002; 46: 2571-2573.
4. Falk RJ, Jennette C, Nachman PH. Primary glomerular disease. In: Brenner HM (ed). The Kidney (7th ed). Saunders: Philadelphia; 2004. p. 1343-1380.
5. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine. 1991; 70: 246-256.
6. Nagata M, Shimokama T, Harada A, Koyama A, Watanabe T. Glomerular crescents in renal amyloidosis: an epiphenomenon or distinct pathology? Pathol Int. 2001; 51: 179-186.
7. Saint Marcoux B, De Bandt M. Vasculitides induced by TNF-α antagonists: a study in 39 patients in France. Joint Bone Spine. 2006; 73: 710-713.
8. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002; 122: 1592-1608.
9. Schafernak KT, Chugh SS, Kanwar YS. Co-existent crescentic glomerulonephritis and renal amyloidosis: a case report and literature review. J Nephrol. 2005; 18: 616-622.
10. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D'Agati VD. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005; 20: 1400-1406.
11. Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M. Biological and clinical effects of anti-TNF-α treatment. Autoimmun Rev. 2007; 7: 35-41.
12. Verschueren P, Lensen F, Lerut E, Claes K, De Vos R, Van Damme B, Westhovens R. Benefit of anti-TNF-α treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis. 2003; 62: 368-369 (letter).
13. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001; 7: 295-300.